Home › Esophageal Adenocarcinoma › Massachusetts
Pag-aaral pangklinika para sa Esophageal Adenocarcinoma sa Massachusetts
13 pag-aaral para sa Esophageal Adenocarcinoma ang naghahanap ng mga kalahok sa mga site sa Massachusetts.
Mga Lungsod sa Massachusetts
Opisyal na teksto ng pag-aaral (English)
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
- Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT07544589mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- Boston Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute at Boston Medical Center - Brighton, Brighton
- at 4 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05677490A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute - Chestnut Hill, Newton
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT07090499Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT06324357Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
- Massachusetts General Hospital, Boston
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT07546812Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
- Beth Israel Deaconess Medical Center, Boston
Nagre-recruit
Edad 18 hanggang 89 · Lahat ng kasarian · Na-update Set 11, 2026 · NCT05753748Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Boston
- Research Site, Burlington
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT07431281A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 18, 2026 · NCT07182149A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- at 3 pa
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT04389632Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
- Dana-Farber Cancer Institute, Boston
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 30, 2026 · NCT07675967First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
- Research Site, Boston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 12, 2026 · NCT07284186Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
- I-Mab Site 1002, Boston
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update May 14, 2026 · NCT07432295Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- Mass General Hospital, Boston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 5, 2026 · NCT04900818Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.